Thrombotic and Bleeding Complications in Myeloproliferative Neoplasms: An Integrated Clinical Perspective
Seminars in Thrombosis and Hemostasis · 08.04.2026
DOI: 10.1055/a-2836-0670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 08.04.2026. Verfasst von Omri Cohen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine, Kaplan Medical Center and The Hebrew University of Jerusalem, Jerusalem, Israel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Abstract (Originalsprache)
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders characterized by elevated thrombotic and bleeding risk, and optimal risk stratification and management remain challenging. This review summarizes current evidence on the thrombotic complications in MPNs, including venous events (i.e., deep vein thrombosis, pulmonary embolism, and unusual site thrombosis), and arterial events (ischemic stroke, myocardial infarction, and peripheral arterial thrombosis), and the increased bleeding risk in these diseases. Mechanistically, JAK2-driven clonal hematopoiesis, elevated hematocrit, leukocytosis, platelet activation, endothelial dysfunction, and chronic inflammation interact to promote a pro-thrombotic state; conversely, extreme thrombocytosis, acquired von Willebrand syndrome, and anticoagulant/antiplatelet therapy contribute to bleeding risk. Clinically, thrombosis may precede MPN diagnosis, especially in unusual sites, and treatment should balance the risk of recurrent thrombosis against the risk of hemorrhagic complications. Antithrombotic strategies include low-dose aspirin, vitamin K antagonists, and direct oral anticoagulants, while cytoreductive therapy (hydroxyurea, anagrelide, interferon, and JAK inhibitors) is central for disease control as well as vascular risk reduction. Despite therapy, recurrence of thrombotic events and major bleeding persists, highlighting the need for optimized risk models and alternative therapeutic targets. Future research may focus on integrating molecular biomarkers, inflammation metrics, and vascular-specific endpoints to direct personalized preventive strategies.
Autor:innen und Institutionen
- Department of Transfusion Medicine, Kaplan Medical Center and The Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Medicine and Surgery, University of Insubria, Varese, Italy.
- Gray Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Hematology Institute and Blood Bank, Meir Medical Center, Kfar Saba, Israel.
Zitieren
APA
Cohen, O., & Ellis, M. H. (2026). Thrombotic and Bleeding Complications in Myeloproliferative Neoplasms: An Integrated Clinical Perspective. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/a-2836-0670
Vancouver
Cohen O, Ellis MH. Thrombotic and Bleeding Complications in Myeloproliferative Neoplasms: An Integrated Clinical Perspective. Seminars in Thrombosis and Hemostasis. 2026. doi:10.1055/a-2836-0670
BibTeX
@article{Cohen2026,
author = {Cohen, Omri and Ellis, Martin H},
title = {Thrombotic and Bleeding Complications in Myeloproliferative Neoplasms: An Integrated Clinical Perspective},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
doi = {10.1055/a-2836-0670}
}
EUVIMED